Franciele Fátima Lopes

Ms. Franciele Fátima Lopes

Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
FLFranciele Fátima Lopes
Franciele Fátima Lopes
JFJéssica Lamberty Faverzani
Jéssica Lamberty Faverzani
THTatiane Hammerschmidt
Tatiane Hammerschmidt
CDCamila Aguilar Delgado
Camila Aguilar Delgado
JOJulia Ferreira de Oliveira
Julia Ferreira de Oliveira
CVCarmen Vargas
Carmen Vargas

27 August 2022 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
CJCarlos Eduardo Diaz Jacques
Carlos Eduardo Diaz Jacques
FLFranciele Fátima Lopes
Franciele Fátima Lopes
EPEdina Poletto
Edina Poletto
LVLuisa Natalia Pimentel Vera
Luisa Natalia Pimentel Vera
PVPriscila Vianna
Priscila Vianna
CVCarmen Vargas
Carmen Vargas

30 September 2022 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
FLFranciele Fátima Lopes
Franciele Fátima Lopes
ASAngela Sitta
Angela Sitta
DCDaniella de Moura Coelho
Daniella de Moura Coelho
GRGraziela Schmitt Ribas
Graziela Schmitt Ribas
JFJéssica Lamberty Faverzani
Jéssica Lamberty Faverzani
CVCarmen Regla Vargas
Carmen Regla Vargas

Verified
Journal Article
Open access
PDF file
Francyne KubaskiFrancyne Kubaski
Francyne Kubaski
alberto burlinaalberto burlina
alberto burlina
Giulia PoloGiulia Polo
Giulia Polo
DPDanilo Pereira
Danilo Pereira
ZHZackary Michel Herbst
Zackary Michel Herbst
Roberto GiuglianiRoberto Giugliani
Roberto Giugliani
Niemann-Pick disease type C (NPC) is a lysosomal disorder caused by impaired cholesterol metabolism. Levels of lysosphingomyelin 509 (LysoSM509) have been shown elevated in dried blood spots (DBS) of NPC and acid sphingomyelinase deficiency patients. In this study, we report our experience using a two-tier approach (1st tier is the quantification of lysoSM509 by ultra-performance liquid chromatography tandem mass spectrometry followed by the 2nd tier with next-generation sequencing of the NPC1 and NPC2 genes). DBS samples from 450 suspected patients were received by the NPC Brazil network. Of these, 33 samples had elevated levels of lysoSM509, and in 25 of them, variants classified as pathogenic, likely pathogenic, or of unknown significance were identified in the NPC1 or NPC2 genes by next-generation sequencing. The quantification of lysoSM509 in DBS as a first-tier test for the diagnosis of NPC followed by molecular analysis of the NPC1 and NPC2 genes almost doubled the detection rate when compared to the performance of chitotriosidase activity as a first-tier biomarker, and it could likely be increased with the addition of a third tier with MLPA of the two genes involved. This strategy seems suitable for the neonatal screening (NBS) of NPC if this disease is eventually adopted by NBS programs.

26 September 2025 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
RMRoberta Barbizan Mascarello
Roberta Barbizan Mascarello
JFJéssica Lamberty Faverzani
Jéssica Lamberty Faverzani
FLFranciele Fátima Lopes
Franciele Fátima Lopes
LTLuísa Maria Bosquetti Tedesco
Luísa Maria Bosquetti Tedesco
ABAna Kalise Böttcher
Ana Kalise Böttcher
CVCarmen Vargas
Carmen Vargas